Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

India Hill

Dermatology Birmingham, AL Medical Doctor

NPI 1245675834 CMS profile 1392351

1940 Elmer J Bissell Rd, Birmingham, AL 35243

Open in the dashboard

General payments

$7,788

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, India Hill of Birmingham, AL is reported in the CMS Open Payments database as having received $7,788 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,018 23
2024 General $785 12
2023 General $587 12
2022 General $412 8
2021 General $2,506 9
2020 General $2,351 10
2019 General $130 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • India Hill
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to India Hill were reported at $1,018. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year India Hill Dermatology median Middle half National median
2019 $130 $454 $129–$1,240 $163
2020 $2,351 $235 $81–$756 $114
2021 $2,506 $377 $108–$1,108 $132
2022 $412 $514 $143–$1,391 $149
2023 $587 $607 $159–$1,674 $160
2024 $785 $751 $204–$1,903 $164
2025 $1,018 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $2,422 6 payments
  2. Regeneron Healthcare Solutions, Inc. $2,214 3 payments
  3. Genzyme Corporation $1,114 24 payments
  4. Novartis Pharmaceuticals Corporation $891 11 payments
  5. E.R. Squibb & Sons, L.L.C. $208 2 payments
  6. Galderma Laboratories, L.P. $191 6 payments
  7. AbbVie, Inc. $185 9 payments
  8. LEO Pharma Inc. $176 3 payments
  9. Dermavant Sciences, Inc. $108 1 payment
  10. Akorn, Inc. $79 1 payment
  11. Other $200 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,608 74 payments
  2. Honoraria $2,100 1 payment
  3. Consulting Fee $2,080 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $2,214 3 payments
  2. EUCRISA $2,137 3 payments
  3. DUPIXENT Immunology $953 25 payments
  4. VIJOICE $457 7 payments
  5. LITFULO $285 3 payments
  6. NEMLUVIO $191 6 payments
  7. ADBRY $176 3 payments
  8. RINVOQ $142 7 payments
  9. VTAMA $131 2 payments
  10. SOTYKTU $90 1 payment
  11. Other $379 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record